Intravitreal propranolol in patient with persistent clinically significant diabetic macular edema

Intravitreal propranolol in patient with persistent clinically significant diabetic macular edema: A single Armed Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231027059872N1

Enrollment

Registered

2024-06-15

Start date

2023-11-22

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory diabetic macular edema. Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema

Interventions

Intervention group: diabetic patients resistant to routine medical treatment (bevacizumab). Control group: the same patients with macular edema treated before propranolol injection. For patients in th

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic and refractory DME who have been treated with Avastin at least nine times.

Exclusion criteria

Exclusion criteria: Patients who do not have proper follow-up for diabetic retinopathy Patients without diet and medication for diabetes treatment end stage patients for diabetic retinopathy (legal blindness, neovascular glaucoma, retinal tear, etc.)

Design outcomes

Primary

Measure	Time frame
The thickness of the macula is normally between 228-330 micrometers. This value increases in patients with diabetic macular edema. In this study, we expect the central thickness of the macula to decrease by about 100 microns. Timepoint: 1week/4week/8week. Method of measurement: Optical coherence tomography (oct).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Akam salehi

Tabriz University of Medical Sciences

seyvan8@gmail.com+98 41 3657 7331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026